Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Lleida – page 6

188 clinical trials in Lleida, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Lleida at a glance
188
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

188 trials in Lleida

Open in trial search

Glomerulonephritis rapidly progressive

Recruiting

Study on the Safety and Tolerability of Lixudebart and Rituximab for Patients with Rapidly Progressive Glomerulonephritis Due to ANCA-Associated Vasculitis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lixudebart
  • Sponsor:Alentis Therapeutics AG

Breast cancer

Recruiting

Study on the Effectiveness of Inavolisib with Trastuzumab and Pertuzumab for Patients with HER2-Positive, HR-Positive, PIK3CA Mutant Early Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:GBG Forschungs GmbH

Hormone receptor positive breast cancer

Recruiting

Study on Elacestrant and Triptorelin for Premenopausal Women with Early Luminal Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tamoxifen Citrate
  • Sponsor:Solti Group

Dilated cardiomyopathy+1

Recruiting

Study on Early Use of Candesartan vs Placebo for People with Genetic Risk of Dilated Cardiomyopathy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Candesartan Cilexetil
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda

Triple negative breast cancer

Recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gilead Sciences Inc.

Immunisation+3

Not yet recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:Sanofi Pasteur Inc.

Type 2 diabetes mellitus+2

Not yet recruiting

Effect of lenbelintide (AZD6234) on body weight in adults with type 2 diabetes and obesity or overweight

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Breast cancer

Not yet recruiting

Discontinuation of anti‑HER2 therapy guided by ctDNA in patients with HER2‑positive metastatic breast cancer receiving pertuzumab and trastuzumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana

Colorectal cancer metastatic

Not yet recruiting

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Genmab A/S

IgA nephropathy

Not yet recruiting

Study of ARGX-121 to Reduce Proteinuria in Adults with Primary IgA Nephropathy (IgAN)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Argenx

Prodromal Alzheimer's disease

Not yet recruiting

Efficacy and Safety of Trontinemab with [18F]MK-6240 in Cognitively Unimpaired Individuals at Risk for Alzheimer’s Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Lleida

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, including studies for HER2-positive and triple-negative variants. Research includes evaluation of new therapeutic approaches for lung cancer and colorectal cancer.

  • Advanced breast cancer therapies
  • Non-small cell lung cancer treatments
  • Gastrointestinal cancer interventions

Multiple studies are examining targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Neurological Disorders

Ground-breaking research into Alzheimer's Disease treatments, including studies on associated psychosis and early-stage interventions. Investigations of novel therapeutic approaches for various neurological conditions.

  • Early Alzheimer's treatment
  • Myasthenia Gravis management
  • Neuroinflammation studies

Focus on developing innovative treatments to address both symptoms and disease progression.

03 Metabolic Conditions

Studies examining treatments for Type 2 Diabetes and obesity, with emphasis on weight management and metabolic control. Research includes evaluation of new therapeutic compounds.

  • Diabetes management
  • Weight control interventions
  • Metabolic disorder treatments

Trials aim to improve patient outcomes through innovative therapeutic approaches.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.